Metastasis and bone loss: Advancing treatment and prevention

Cancer Treatment Reviews

Volumn 36, Issue 8, 2010, Pages 615-620

  Coleman, Robert E ^a   Lipton, Allan ^b   Roodman, G David ^c   Guise, Theresa A ^d   Boyce, Brendon F ^e   Brufsky, Adam M ^f   Clézardin, Philippe ^g   Croucher, Peter I ^h   Gralow, Julie R ⁱ   Hadji, Peyman ^j,k   Holen, Ingunn ^h   Mundy, Gregory R ^l   Smith, Matthew R ^m   Suva, Larry J ⁿ  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^g INSERM   (France)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY HOSPITAL MARBURG   (Germany)

^k Marburg GmbH ^*  (Germany)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

more..

Author keywords

Bisphosphonate; Bone loss; Bone targeted; Denosumab; Metastasis; PTHrP; RANK; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; DICKKOPF 1 PROTEIN; IBANDRONIC ACID; LETROZOLE; ODANACATIB; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; TOREMIFENE; WNT PROTEIN; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; FRACTURE; HUMAN; IMMUNOCOMPETENT CELL; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PROSTATE CANCER; REVIEW; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; OSTEOPOROSIS; PRIMARY PREVENTION; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 78349307345     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.04.003     Document Type: Review

References (61)

1. Guise T.A., Yin J.J., Taylor S.D., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996, 98:1544-1549.
2. Engler A.J., Sen S., Sweeney H.L., Discher D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689.
3. Sterling J.A., Oyajobi B.A. The hedgegog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastaic human breast cancer cells. Cancer Res 2006, 66:7548-7553.
4. Tian E., Zhan F., Walker R., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
5. Yaccoby S., Ling W., Zhan F., et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
6. Heath D.J., Chantry A.D., Buckle C.H., et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009, 24:425-436.
7. Edwards C.M., Edwards J.R., Lwin S.T., et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008, 111:2833-2842.
8. Clézardin P. Insights into the antitumor effects of BPs from preclinical models and potential clinical implications. IBMS BoneKE 2009, 6:210-217.
9. Stresing V., Daubiné F., Benzaid I., Mönkkönen H., Clézardin P. BPs in cancer therapy. Cancer Lett 2007, 257:16-35.
10. Daubiné F., Le Gall C., Gasser J., Green J., Clézardin P. Antitumor effects of clinical dosing regimens of BPs in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99:322-330.
11. Fournier P.G.J., Daubiné F., Lundy M.W., Rogers M.J., Ebetino F.H., Clézardin P. Lowering bone mineral affinity of BPs as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res 2008, 68:8945-8953.
12. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
13. Oyajobi B.O., Anderson D.M., Traianedes K., Williams P.J., Yoneda T., Mundy G.R. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001, 61:2572-2578.
14. Vanderkerken K., De Leenheer E., Shipman C., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003, 63:287-289.
15. Choi S.J., Cruz J.C., Craig F., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96:671-675.
16. Choi S.J., Oba Y., Gazitt Y., et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001, 108:1833-1841.
17. Menu E., De Leenheer E., De Raeve H., et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis 2006, 23:291-300.
18. Iguchi H., Tanaka S., Ozawa Y., et al. An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res 1996, 56:4040-4043.
19. Yin J.J., Selander K., Chirgwin J.M., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999, 103:197-206.
20. Ehata S., Hanyu A., Fujime M., et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007, 98:127-133.
21. Sung B., Murakami A., Oyajobi B.O., Aggarwal B.B. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. Cancer Res 2009, 69:1477-1484.
22. Le Gall C., Bellahcène A., Bonnelye E., et al. Cathepsin K inhibitors as treatment of bone metastasis. Cancer Res 2007, 67:9894-9902.
23. Rucci N., Recchia I., Angelucci A., et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice. Implications for therapy. J Pharmacol Exp Ther 2006, 318:161-172.
24. Ports M.O., Nagle R.B., Pond G.D., Cress A.E. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res 2009, 69:5007-5114.
25. Yin J.J., Mohammad K.S., Kakonen S.M., et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003, 100:10954-10959.
26. Zhao Y., Bachelier R., Treilleux I., et al. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 2007, 67:5821-5830.
27. Brown H.K., Holen I. Anti-tumour effects of bisphosphonates - what have we learned from in vivo models?. Curr Cancer Drug Targets 2009, 9:807-823.
28. Wang Y., Wan C., Deng L., Liu X., et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007, 117:1616-1626.
29. Cackowski F.C., Anderson J.L., Patrene K.D., et al. Osteoclasts are important for bone angiogenesis. Blood 2010, 115:140-149.
30. Aft R., Watson M., Ylagan L., et al. Effect of zoledroninc acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 2008, 26:46S. [abstract 1021].
31. Lin A.Y., Park J.W., Scott J., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. Proc Am Soc Clin Oncol 2008, 26:20S. [abstract 559].
32. Rack B.K., Jueckstock J., Genss E.-M., et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Breast Cancer Res Treat 2007, 206:S40. [abstract 511].
33. Diel I.J., Solomayer E.F., Costa S.D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
34. Powles T., Paterson A., McCloskey E., et al. Reduction in bone relapse, improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006, 8:R13.
35. Saarto T., Blomqvist C., Virkkunen P., Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patient: 5-year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
36. Jaschke A., Bastert G., Slolmayer E.F., et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastses to bone marrow - longtime followup. Proc Am Soc Clin Oncol 2004, 22:9s. [abstract 529].
37. Ha T.C., Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007, 96:1796-1801.
38. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
39. Brufsky A., Bundred N., Coleman R., et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13:503-514.
40. Stopeck A, Body JJ, Fujimawara Y, et al. Denosumab demonstrates superiority over Zometa(R) in delay of complications due to bone metastases in advanced breast cancer patients ECCO/ESMO; 2009 [abstract 2LBA].
41. Henry D, von Moos R, Vadhan-Raj V, et al. A double-blind randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (exclusing breast and prostate cancer) or multiple myeloma. ECCO/ESMO; 2009 [abstract 20LBA].
42. Jensen A.B., Olmeo N., Wynne C., et al. Effect of cathepsin k inhibition on suppression of bone resorption in women with breast cancer, established bone metastases in a 4-week, double-blind, randomized controlled trial. J Clin Oncol ASCO Proceedings 2008, 26:1023.
43. Boyce B.F., Xing L., Yao Z., et al. Src inhibitors in metastatic bone disease. Clin Cancer Res 2006, 12:6291s-6295s.
44. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
45. Adachi J.D., Ioannidis G., Olszynski W.P., et al. The impact of incident vertebral, non-vertebral fractures on health related quality of life in postmenopausal women. BMC Musculoskelet Disord 2002, 3:11.
46. Whannel K.J., McLellan A., Wilson C.R., Doughty J.C. The need for DXA assessment of breast cancer patients following 5 years tamoxifen prior to starting an aromatase inhibitor. Breast Cancer Res Treat 2006, 100:S187. [abstract 4046].
47. Eidtmann H., Bundred N.J., DeBoer R., et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res 2008, 69. [abstract 44].
48. Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
49. Lombarto AL, Frassoldati A, Paija O, et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. In: 2009 ASCO Breast Cancer Symposium [abstract 213].
50. Gnant M.F., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer. J Clin Oncol 2007, 25:820-828.
51. Van Poznak C., Hannon R.A., Clack G., et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. Breast Cancer Res Treat 2007, 106:S37. [abstract 502].
52. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
53. Ellis G.K., Bone H.G., Chlebowski R., et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009, 118:81-87.
54. Logman F, Heeg B., Botteman M, et al. Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: application to the United Kingdom. ECCO; September 2007 [abstract 1146].
55. Hadji P., Body J.J., Aapro M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.
56. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
57. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 2001, 345:948-955.
58. Smith M.R., Eastham J., Gleason D., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
59. Greenspan S.L., Nelson J.B., Trump D.L., Resnick N.M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416-424.
60. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008, 179:152-155.
61. Smith M.R., Egerdie B., Hernandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.